BioCardia Net Income 2006-2021 | BCDA

BioCardia net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
BioCardia Annual Net Income
(Millions of US $)
2020 $-15
2019 $-15
2018 $-14
2017 $-12
2016 $-10
2015 $-7
2014 $0
2013 $0
2012 $0
2011 $10
2010 $-12
2009 $-5
2008 $-6
2007 $-0
2007 $-0
2006 $-0
2005 $-1
BioCardia Quarterly Net Income
(Millions of US $)
2021-09-30 $-3
2021-06-30 $-3
2021-03-31 $-3
2020-12-31 $-3
2020-09-30 $-4
2020-06-30 $-4
2020-03-31 $-5
2019-12-31 $-4
2019-09-30 $-4
2019-06-30 $-4
2019-03-31 $-4
2018-12-31 $-4
2018-09-30 $-4
2018-06-30 $-3
2018-03-31 $-4
2017-12-31 $-3
2017-09-30 $-3
2017-06-30 $-3
2017-03-31 $-3
2016-12-31 $-4
2016-09-30 $-3
2016-06-30 $-2
2016-03-31 $-1
2015-12-31 $-7
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $-0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $-0
2012-03-31 $-0
2011-12-31 $-0
2011-09-30 $-1
2011-06-30 $11
2011-03-31 $-0
2010-12-31 $-0
2010-09-30 $-8
2010-06-30 $-1
2010-03-31 $-1
2009-12-31 $-1
2009-09-30 $-1
2009-06-30 $-1
2009-03-31 $-1
2008-12-31 $-3
2008-09-30 $-1
2008-06-30 $-2
2008-03-31 $-0
2007-12-31 $-0
2007-09-30 $-0
2007-06-30
2007-03-31 $-0
2006-12-31 $-0
2006-09-30 $-0
2006-06-30
2006-03-31 $-0
2005-12-31 $-0
2005-09-30 $-0
2005-06-30
2005-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.035B $0.000B
BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.969B 7.71
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.359B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $7.214B 0.00
Arcus Biosciences (RCUS) United States $3.030B 0.00
Emergent Biosolutions (EBS) United States $2.347B 8.44
ADC Therapeutics SA (ADCT) Switzerland $1.505B 0.00
Myovant Sciences (MYOV) United Kingdom $1.429B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.366B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09